评估高剂量、佐剂和重组流感疫苗对细胞培养A(H3N2)病毒免疫原性的临床试验:2017-2018年65至74岁成人
在65-74岁成人中开展开放标签随机免疫原性试验,比较高剂量三价灭活疫苗(HD-IIV3)、佐剂三价灭活疫苗(aIIV3)和四价重组疫苗(RIV4)对细胞培养A(H3N2)病毒的免疫原性。各组对疫苗株的中和抗体应答均不理想,但RIV4对循环和抗原进化病毒产生更强的交叉保护应答。
要点
- 各组对疫苗株的接种后几何平均滴度均<1:60,血清转换率<15%。
- RIV4对3C.2a1和3C.2a2病毒的平均倍数增长约为HD-IIV3和aIIV3的两倍。
- RIV4对3C.3a病毒的平均倍数增长高于HD-IIV3和aIIV3。
核心结论
- 高剂量、佐剂和重组疫苗对细胞培养疫苗株均产生次优的中和抗体应答,但RIV4对循环和抗原进化病毒产生更强的交叉保护应答。
- 重组技术可能有助于开发更广谱保护的流感疫苗,需要进行比较有效性研究。
研究设计与样本
- 2017-2018年开展的为期2年、开放标签免疫原性试验(ClinicalTrials.gov: NCT02872311)的探索性研究。
- 89名65-74岁成人按1:1:1随机接种HD-IIV3、aIIV3或RIV4,此前在2016-17年接种过标准剂量IIV3。
- 基线及接种后第28天采血,用四种细胞培养A(H3N2)病毒(疫苗株3C.2a、循环株3C.2a1和3C.2a2、抗原进化株3C.3a)测定微量中和滴度。
- 进行主动监测以识别流感疾病。
主要发现
- 各组对疫苗株的接种后几何平均滴度(GMT)均<1:60,血清转换率<15%。
- RIV4对疫苗株的平均倍数增长为2.0(95%CI 1.7-2.5),HD-IIV3为1.6(95%CI 1.3-1.8)。
- RIV4对3C.2a1和3C.2a2病毒的接种后滴度更高,平均倍数增长分别为3.3和3.5,HD-IIV3分别为1.4和1.6,aIIV3分别为1.7和1.6。
- 对3C.3a病毒,RIV4的平均倍数增长为2.9(95%CI 2.0-4.3),HD-IIV3为1.3(95%CI 1.1-1.6),aIIV3为1.7(95%CI 1.3-2.1)。
- 后续流感季节7名PCR确诊A(H3N2)感染者中,5名对3C.2a2的接种后滴度≥1:40。
关键数值与推荐
- 对疫苗株的接种后GMT<1:60,血清转换率<15%。
- RIV4对疫苗株平均倍数增长2.0(95%CI 1.7-2.5),HD-IIV3为1.6(95%CI 1.3-1.8)。
- RIV4对3C.2a1和3C.2a2平均倍数增长3.3和3.5,HD-IIV3为1.4和1.6,aIIV3为1.7和1.6。
- RIV4对3C.3a平均倍数增长2.9(95%CI 2.0-4.3),HD-IIV3为1.3(95%CI 1.1-1.6),aIIV3为1.7(95%CI 1.3-2.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Licensed inactivated influenza vaccines (IIV) are recommended for persons aged ≥65 years, including trivalent high-dose IIV (HD-IIV3) and adjuvanted IIV (aIIV3); both are manufactured in eggs. Quadrivalent recombinant vaccine (RIV4) is produced without eggs. We conducted an exploratory study to compare immunogenicity of HD-IIV3, aIIV3 and RIV4 against cell-grown vaccine and circulating A(H3N2) viruses in 2017-18. METHODS: Eighty-nine adults aged 65-74 years participating in a 2-year, open-label immunogenicity trial (ClinicalTrails.gov: NCT02872311) were randomized 1:1:1 to receive HD-IIV3, aIIV3, or RIV4 after receipt of standard dose IIV3 in 2016-17. Serum was obtained at baseline and day 28 post vaccination. Microneutralization titers were determined using four cell-propagated A(H3N2) viruses: 2017-18 vaccine strain (clade 3C.2a), circulating viruses from clades 3C.2a1 and 3C.2a2, and 'antigenically advanced' clade 3C.3a (2019-20 vaccine strain). Active surveillance was conducted to identify influenza illnesses. RESULTS: Post vaccination geometric mean titer (GMT) against the vaccine strain was <1:60 in each group and <15% seroconverted. RIV4 generated a greater fold-rise (2.0, 95% CI 1.7-2.5) compared to HD-IIV3 (1.6, 95% CI 1.3-1.8). RIV4 generated higher post vaccination titers against 3C.2a1 and 3C.2a2 viruses, and the mean fold-rise after RIV4 was twice as high (3.3 and 3.5, respectively) relative to HD-IIV3 (1.4 and 1.6) and aIIV3 (1.7 and 1.6). Against the antigenically advanced 3C.3a virus, RIV4 generated a greater mean fold-rise (2.9, 95% CI 2.0-4.3) vs HD-IIV3 (1.3, 95% CI 1.1-1.6) and aIIV3 (1.7, 95% CI 1.3-2.1). Postvaccination titers against 3C.2a2 were ≥1:40 in 5 of 7 participants with PCR-confirmed A(H3N2) infection during the ensuing influenza season. CONCLUSION: High-dose, adjuvanted, and recombinant vaccines generated suboptimal neutralizing antibody responses to the cell-grown vaccine strain, but RIV4 generated a greater cross-protective response against circulating and antigenically advanced viruses. Recombinant technology may contribute to more broadly protective influenza vaccines, and comparative effectiveness studies are needed.
引用
- Belongia EA, Levine MZ, Olaiya O, et al. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018. Vaccine. 2020. PMID: 32145994. doi:10.1016/j.vaccine.2020.02.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。